News and Trends 20 Dec 2016 These are our 10 Most Read Biotech Articles of 2016 From the hottest research areas to the most popular city for biotech, which biotech articles have managed to hook our readers the most this year? After an exciting journey of 2 years, Labiotech.eu is now the leading biotech media in Europe, with over 50k monthly readers. To celebrate the end of another amazing year, we wanted […] December 20, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Amryt has taken out a loan from the European Investment Bank to fund […] December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Our Startup Battle Winner uses CRISPR in a Whole New Way Eligo Bioscience came out on top in the Startup Battle at Labiotech Refresh, watch the founder’s pitch to see how! CRISPR can be used to cut and replace virtually any gene, which has fueled a fierce patent battle over the rights to use it for gene therapy in humans. Eligo Bioscience, however, focuses on using this powerful tool to […] December 9, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 UPDATE: No Clear Winner in the CRISPR Patent Battle Today marks an inflection point in the future of medicine: both parties fighting for the ownership of CRISPR have made their oral arguments in front of a jury. Who will win the rights to exploit a technology that could be used to cure any genetic disease? CRISPR has been hailed as the ‘scientific discovery of the […] December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2016 Evotec gets hold of CRISPR in a new Partnership with Merck Evotec teamed up with Merck to boost its drug discovery services with CRISPR, entering the battlefield for the patent behind the discovery of the century. Apart from being a pioneer in the translation of research from academia to the clinic, Evotec is a successful CRO with top-level partners including Bayer, Roche, Sanofi, Boehringer Ingelheim and Takeda. The German company is […] December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 CRISPR meets RNAi: a whole new Targeted Therapy Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 How much of a Gamble is Investing in CRISPR? CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely […] November 15, 2016 - 4 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2016 Swiss SynBio adds CRISPR to its Toolkit for new Specialty Chemicals Evolva is licensing the CRISPR patents of Emmanuelle Charpentier, in a deal with holding company ERS Genomics. This will grant access to the wonder gene-editing technology for one of the most important players in European SynBio. Headquartered in Switzerland, Evolva develops new ways to obtain ingredients and specialty chemicals with brewing and engineered microorganisms. Its […] November 8, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2016 CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged? Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […] October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 The CRISPR Revolution is here, but how can we make it Useful? By this point, you can’t have escaped hearing about CRISPR. First discovered in the 1980’s, the repeated sequences and their function in bacterial defense systems remained a mystery until almost 10 years ago, when it was hailed as the biggest scientific discovery of the century. Since then, scientists have leveraged the adaptable, heritable mechanism to develop the most powerful gene-editing technology […] October 10, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2016 CRISPR will Win the Nobel Prize, but When? Not this year… Nobel Prize week has kicked off with the announcement of Physiology and Medicine recipient: it wasn’t the CRISPR crowd, but Yoshinori Ohsumi for his work on autophagy. As Derek Lowe puts it, CRISPR “is absolutely, positively going to win a Nobel; the only question is when.” Well, it didn’t manage last year, nor this year. […] October 4, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email